BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24341609)

  • 1. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.
    Du X; Yang J; Ylipää A; Zhu Z
    J Hematol Oncol; 2013 Dec; 6():93. PubMed ID: 24341609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.
    Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
    Clin Cancer Res; 2011 Dec; 17(24):7563-73. PubMed ID: 22042973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
    Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
    Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
    Jia X; Chen L; Yu C
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
    Yu J; Deshmukh H; Payton JE; Dunham C; Scheithauer BW; Tihan T; Prayson RA; Guha A; Bridge JA; Ferner RE; Lindberg GM; Gutmann RJ; Emnett RJ; Salavaggione L; Gutmann DH; Nagarajan R; Watson MA; Perry A
    Clin Cancer Res; 2011 Apr; 17(7):1924-34. PubMed ID: 21325289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.
    Rahrmann EP; Moriarity BS; Otto GM; Watson AL; Choi K; Collins MH; Wallace M; Webber BR; Forster CL; Rizzardi AE; Schmechel SC; Ratner N; Largaespada DA
    Am J Pathol; 2014 Jul; 184(7):2082-98. PubMed ID: 24832557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
    Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
    Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
    Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor.
    Pryor JG; Brown-Kipphut BA; Iqbal A; Scott GA
    Am J Dermatopathol; 2011 Dec; 33(8):780-5. PubMed ID: 21785329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands.
    Byer SJ; Brossier NM; Peavler LT; Eckert JM; Watkins S; Roth KA; Carroll SL
    J Neuropathol Exp Neurol; 2013 Mar; 72(3):219-33. PubMed ID: 23399900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
    Dilworth JT; Wojtkowiak JW; Mathieu P; Tainsky MA; Reiners JJ; Mattingly RR; Hancock CN
    Cancer Biol Ther; 2008 Dec; 7(12):1938-46. PubMed ID: 18927496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
    Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
    J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
    Gong M; Ma J; Li M; Zhou M; Hock JM; Yu X
    Neuro Oncol; 2012 Aug; 14(8):1007-17. PubMed ID: 22718995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.
    Skotheim RI; Kallioniemi A; Bjerkhagen B; Mertens F; Brekke HR; Monni O; Mousses S; Mandahl N; Soeter G; Nesland JM; Smeland S; Kallioniemi OP; Lothe RA
    J Clin Oncol; 2003 Dec; 21(24):4586-91. PubMed ID: 14673046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
    Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
    Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
    Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
    J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
    Qin W; Godec A; Zhang X; Zhu C; Shao J; Tao Y; Bu X; Hirbe AC
    Cancer Med; 2019 Sep; 8(11):5232-5241. PubMed ID: 31278855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms.
    Perry A; Kunz SN; Fuller CE; Banerjee R; Marley EF; Liapis H; Watson MA; Gutmann DH
    J Neuropathol Exp Neurol; 2002 Aug; 61(8):702-9. PubMed ID: 12152785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.